Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer.
BRCA1/2
HGSOC
fibrosis
homologous recombination deficiency
mesenchymal
prognosis
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
12
2019
accepted:
24
02
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
High-grade serous ovarian cancer is one of the deadliest gynecological malignancies and remains a clinical challenge. There is a critical need to effectively define patient stratification in a clinical setting. In this study, we address this question and determine the optimal number of molecular subgroups for ovarian cancer patients. By studying several independent patient cohorts, we observed that classifying high-grade serous ovarian tumors into four molecular subgroups using a transcriptomic-based approach did not reproducibly predict patient survival. In contrast, classifying these tumors into only two molecular subgroups, fibrosis and non-fibrosis, could reliably inform on patient survival. In addition, we found complementarity between transcriptomic data and the genomic signature for homologous recombination deficiency (HRD) that helped in defining prognosis of ovarian cancer patients. We also established that the transcriptomic and genomic signatures underlined independent biological processes and defined four different risk populations. Thus, combining genomic and transcriptomic information appears as the most appropriate stratification method to reliably subgroup high-grade serous ovarian cancer patients. This method can easily be transferred into the clinical setting.
Identifiants
pubmed: 32256521
doi: 10.3389/fgene.2020.00219
pmc: PMC7089941
doi:
Banques de données
figshare
['10.6084/m9.figshare.11663232']
Types de publication
Journal Article
Langues
eng
Pagination
219Informations de copyright
Copyright © 2020 Kieffer, Bonneau, Popova, Rouzier, Stern and Mechta-Grigoriou.
Références
Br J Cancer. 2011 Jul 12;105(2):304-11
pubmed: 21654678
Oncotarget. 2015 Nov 3;6(34):36815-24
pubmed: 26416421
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Int J Cancer. 2015 Oct 15;137(8):1890-900
pubmed: 25892415
Clin Cancer Res. 2017 Jul 15;23(14):3794-3801
pubmed: 28159814
J Clin Oncol. 2012 Feb 1;30(4):372-9
pubmed: 22203755
Cancer Res. 2012 Jun 1;72(11):2701-4
pubmed: 22593197
Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11
pubmed: 27673289
Nat Commun. 2016 Jan 04;7:8959
pubmed: 26725650
BMC Cancer. 2012 Dec 28;12:627
pubmed: 23272653
Acta Obstet Gynecol Scand. 2016 May;95(5):505-12
pubmed: 26910180
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Cancer Res. 2012 Nov 1;72(21):5454-62
pubmed: 22933060
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
N Engl J Med. 2009 Jul 9;361(2):123-34
pubmed: 19553641
Anticancer Res. 2014 Feb;34(2):551-6
pubmed: 24510983
Cancer Treat Rev. 2012 Oct;38(6):662-72
pubmed: 22209539
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Lancet. 2017 Jan 7;389(10064):2
pubmed: 28091366
Cancer Metastasis Rev. 2014 Mar;33(1):17-39
pubmed: 24357056
Oncologist. 2012;17(7):956-62
pubmed: 22673632
Ann Oncol. 2016 Apr;27 Suppl 1:i33-i39
pubmed: 27141068
Lancet Oncol. 2011 Sep;12(9):852-61
pubmed: 21862407
J Oncol. 2012;2012:709049
pubmed: 23319948
PLoS One. 2012;7(2):e30269
pubmed: 22348002
Endocr Relat Cancer. 2010 Dec 21;18(1):85-95
pubmed: 21051560
Tumori. 2016 Oct 13;102(5):433-440
pubmed: 27716873
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Lancet Oncol. 2014 Oct;15(11):1207-14
pubmed: 25218906
PLoS One. 2011;6(7):e21800
pubmed: 21789182
J Clin Oncol. 2010 May 20;28(15):2512-9
pubmed: 20406929
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
Int J Mol Sci. 2015 Jul 24;16(8):16833-47
pubmed: 26213923
Lancet. 2010 Jul 24;376(9737):245-51
pubmed: 20609468
Int J Biochem Cell Biol. 2013 Jun;45(6):1092-8
pubmed: 23500525
BMJ. 2015 Dec 16;351:h6837
pubmed: 26673454
Nat Med. 2011 Nov 20;17(12):1627-35
pubmed: 22101765
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Int J Cancer. 2016 Feb 15;138(4):891-900
pubmed: 26317927
Br J Cancer. 2016 Nov 8;115(10):1157-1173
pubmed: 27736844
Biomed Rep. 2017 Mar;6(3):319-322
pubmed: 28451393
Genome Biol. 2009;10(11):R128
pubmed: 19903341
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038
J Natl Cancer Inst. 2014 Sep 30;106(10):
pubmed: 25269487
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362
Mol Oncol. 2015 Oct;9(8):1678-93
pubmed: 26025631